SL Science Holding Limited is a dynamic company focused on leveraging advanced technologies to drive innovation in the scientific and healthcare sectors. With a commitment to developing cutting-edge solutions, SLBT is positioned to capitalize on emerging market trends and address critical challenges in biotechnology and life sciences. The company's strategic vision emphasizes research and development, fostering partnerships to enhance its product portfolio and expand its market presence. As an emerging player in this rapidly evolving industry, SLBT aims to deliver substantial long-term value for its stakeholders through sustainable growth and innovation.
| Revenue (TTM) | $3.27M |
| Gross Profit (TTM) | $1.26M |
| EBITDA | $-2.28M |
| Operating Margin | -142.50% |
| Return on Equity | -25.60% |
| Return on Assets | -14.70% |
| Revenue/Share (TTM) | $0.89 |
| Book Value | $1.29 |
| Price-to-Book | 397.75 |
| Price-to-Sales (TTM) | 258.94 |
| EV/Revenue | 412.96 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.60% |
| Shares Outstanding | $560.76M |
| Float | 0 |
| % Insiders | 59.55% |
| % Institutions | 0.29% |
Volatility is currently expanding
New findings highlight the therapy's ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence.
SL Science Holding Limited is rated Sell due to an unsustainable $1.15B valuation built on a strictly preclinical pipeline. SLBT's flagship Gamma Delta T cell therapy targets aggressive solid tumors but has not entered human trials, with a very low probability of success. With only $9M in cash, a $3.82M annual loss, and going-concern doubts, imminent dilution is almost certain without a major partnership.
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that its management team rang Nasdaq bell at the Nasdaq MarketSite in Times Square, New York, to celebrate its first quarter as a publicly traded company.
TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed Co., Ltd. (“JY BioMed”), the intellectual property holder of the GDT platform and SL Science's licensor.
Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.
Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). The FDA's Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request and is proceeding with review on additional files about the product
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SLBT and any ticker you trade — then tracks every position and per-strategy win rate.
